Volume 123, Issue 4 , Pages 868-874.e13, April 2009
Prostaglandin E2 suppresses staphylococcal enterotoxin–induced eosinophilia-associated cellular responses dominantly through an E-prostanoid 2–mediated pathway in nasal polyps
Background
Recent investigations have revealed that staphylococcal enterotoxins (SEs), COX metabolism, or both might participate in the pathogenesis of eosinophilic airway diseases, such as chronic rhinosinusitis with nasal polyposis.
Objective
We sought to determine whether COX metabolism, especially prostaglandin (PG) E2, plays a significant role in SE-induced cellular responses in nasal polyps.
Methods
Dispersed nasal polyp cells (DNPCs) were prepared from nasal polyps by means of enzymatic digestion. DNPCs were cultured with SEB in the presence or absence of COX inhibitors (diclofenac and indomethacin) for 72 hours; then the levels of IL-5, IL-13, RANTES, and eotaxin in the supernatants were measured. The effect of PGE2 on SEB-induced responses by diclofenac-treated DNPCs was examined, especially in terms of receptor specificity.
Results
DNPCs produced significant amounts of IL-5, IL-13, and RANTES in response to SEB. COX inhibitors significantly increased the production of these cytokines. The degree of local eosinophilia was significantly and positively correlated with the changes in IL-5 production induced by diclofenac treatment. PGE2 significantly and dose-dependently inhibited SEB-induced IL-5, IL-13, and RANTES production by diclofenac-treated DNPCs. E-prostanoid (EP) 2 receptor–selective agonist strongly inhibited the production of all 3 cytokines. EP3 and EP4 receptor–selective agonists partially suppressed these responses, whereas EP1 receptor–selective agonist did not. Interestingly, all of the combined treatments with 2 of the 4 EP receptor–selective agonists significantly inhibited the SEB-induced responses by diclofenac-treated DNPCs.
Conclusions
These results suggest that PGE2 inhibits the pathogenesis of SEB-induced eosinophilic inflammation primarily through the EP2-mediated pathway in patients with chronic rhinosinusitis with nasal polyposis.
Key words: Enterotoxin, COX, prostaglandin E2, E-prostanoid receptor, IL-5, IL-13, RANTES, nasal polyps, chronic rhinosinusitis
Abbreviations used: CRS-NP, Chronic rhinosinusitis with nasal polyposis, DMSO, Dimethyl sulfoxide, DNPC, Dispersed nasal polyp cell, ECP, Eosinophil cationic protein, EP, E-prostanoid, ICAM-1, Intercellular adhesion molecule 1, m-PGES-1, Microsomal PGE2 synthase 1, NSAID, Nonsteroidal anti-inflammatory drug, PG, Prostaglandin, SE, Staphylococcal enterotoxin
Supported in part by grants from the Ministry of Education, Culture, Sports, Science, and Technology, Japan (19591971).
Disclosure of potential conflict of interest: The authors have declared that they have no conflict of interest.
PII: S0091-6749(09)00166-3
doi:10.1016/j.jaci.2009.01.047
© 2009 American Academy of Allergy, Asthma & Immunology. Published by Elsevier Inc. All rights reserved.
Volume 123, Issue 4 , Pages 868-874.e13, April 2009
